A 2026 PROTECT study involving 174 older adults found that self-administered fingerprick p-tau217 correlated with episodic memory (r = 0.299, p < 0.001) and GFAP correlated with working memory (r = 0.183, p = 0.034), supporting remote Alzheimer's risk triage rather than a stand-alone dementia diagnosis. Research Highlights Fingerprick sampling reached 77% completion: 174 of …
A preprint in 84 older adults with epilepsy found that abnormal Alzheimer's-related blood biomarkers were common, but the biomarker categories did not line up neatly with cognitive impairment. Research Highlights Only 32.1% had normal biomarkers: 27 of 84 older adults with epilepsy were A−T−N− using blood-based amyloid, tau, and neurodegeneration markers.1 AD-continuum profiles were common: …
A 2026 ADNI/A4 validation study found that Alzheimer’s plasma-biomarker machine-learning models still ranked amyloid PET status well across cohorts, but the practical rule-out number moved hard: negative predictive value fell from 0.831 inside ADNI to 0.644 when the ADNI-trained model was applied to A4.1 Research Highlights 1,707-person ADNI/A4 test: researchers trained amyloid PET prediction models …
Until recently, Alzheimer’s pathology could only be confirmed in living patients via PET imaging or lumbar puncture. Plasma p-tau217 changed that calculus — but how to interpret a positive result depends substantially on APOE genotype.1 Research Highlights Plasma p-tau217 is a blood biomarker that rises years before Alzheimer’s symptoms. The 2024 Alzheimer’s Association revised criteria …